Virios Therapeutics Stock (NASDAQ:VIRI)
Previous Close
$0.18
52W Range
$0.16 - $1.10
50D Avg
$0.22
200D Avg
$0.39
Market Cap
$4.94M
Avg Vol (3M)
$1.14M
Beta
1.60
Div Yield
-
VIRI Company Profile
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
VIRI Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. |
| CNSP | CNS Pharmaceuticals, Inc. |
| ICU | SeaStar Medical Holding Corporation |
| PHIO | Phio Pharmaceuticals Corp. |
| REVB | Revelation Biosciences, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| IMMX | Immix Biopharma, Inc. |
| CYTO | Altamira Therapeutics Ltd. |
| SONN | Sonnet BioTherapeutics Holdings, Inc. |
| ZURA | Zura Bio Limited |